Si
Sierra Oncology (GSK)
Vancouver CAFounded 2003100 employees
Private CapbiotechAcquiredHematology
Platform: Momelotinib MF
Market Cap
N/A
All Drugs
4
Clinical Trials
6
Failed / Terminated
1
FDA Approved
0
Drug Pipeline (4 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| Ivofotisoran | SIE-5395 | NDA/BLA | 1 | CD38 | EpilepsyCrohn's | ||
| SIE-6456 | SIE-6456 | Phase 2 | 1 | MALT1 | CML | ||
| SIE-9908 | SIE-9908 | Phase 3 | 2 | VEGF | Ovarian Ca | ||
| Sotolemzoparlimab | SIE-4035 | Phase 1 | 2 | PD-1 | HS |
Financial Documents
This company has been acquired — see parent company for financial filings.
Catalyst Events (4)